InsiderSignal.AI

InsiderSignal.ai

ELVN - Enliven Therapeutics, Inc.

Insider Sale by Heyman Richard A. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Heyman Richard A., serving as Dir at Enliven Therapeutics, Inc. (ELVN), sold 1,230 shares at $26.18 per share, for a total transaction value of $32,196.00. Following this transaction, Heyman Richard A. now holds 171,865 shares of ELVN.

This sale represents a 1.00% decrease in Heyman Richard A.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, February 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 19, 2026, 2 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Heyman Richard A.

Heyman Richard A.

Dir

Richard A. Heyman, Ph.D. is a prominent biotech entrepreneur and scientist with over 25 years of experience in founding and leading companies developing therapies for cancer and other diseases. He earned a PhD in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut, and conducted postdoctoral research at the Salk Institute under Professor Ronald Evans.[[1]](https://inside.salk.edu/fall-2023/richard-heyman-from-salk-to-biotech-and-back/)[[3]](https://www.salk.edu/news-release/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman/) His career includes roles at Ligand Pharmaceuticals, rising to Vice President of Research where his team developed FDA-approved cancer treatments like Panretin® and Targretin®; he co-founded X-Ceptor Therapeutics (acquired by Exelixis), Aragon Pharmaceuticals (acquired by J&J in 2013), and Seragon Pharmaceuticals (acquired by Genentech/Roche in 2014), contributing to drugs like Erleada for prostate cancer.[[1]](https://inside.salk.edu/fall-2023/richard-heyman-from-salk-to-biotech-and-back/)[[2]](https://belharratx.com/team/richard-a-heyman-ph-d/)[[3]](https://www.salk.edu/news-release/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman/) Heyman currently serves as a Director on the Board of Enliven Therapeutics, Inc. (ELVN), where he has recently engaged in insider trading activities, and holds chairmanships or board positions at companies including ORIC Pharmaceuticals, PMV Pharma, Rayze Bio (acquired by BMS in 2023), and others like Vividion Therapeutics (acquired by Bayer) and Amunix Pharma (acquired by Sanofi).[[2]](https://belharratx.com/team/richard-a-heyman-ph-d/)[[5]](https://www.xaira.com/team/richard-a-heyman-phd)[[9]](https://www.gurufocus.com/insider/61682/richard-a.-heyman) He is Vice Chair of the Salk Institute Board of Trustees, serves on the UCSD Moores Cancer Center board, and has received awards such as the Ernst & Young San Diego Regional Entrepreneur of the Year and Endocrine Society Outstanding Innovation Award; he holds over 125 publications and patents.[[1]](https://inside.salk.edu/fall-2023/richard-heyman-from-salk-to-biotech-and-back/)[[2]](https://belharratx.com/team/richard-a-heyman-ph-d/)[[5]](https://www.xaira.com/team/richard-a-heyman-phd)

View full insider profile →

Trade Price

$26.18

Quantity

1,230

Total Value

$32,196.00

Shares Owned

171,865

Trade Date

Tuesday, February 17, 2026

5 days ago

SEC Filing Date

Thursday, February 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Enliven Therapeutics, Inc.

Company Overview

No company information available
View news mentioning ELVN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4127351

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime